Urticaria News and Research

RSS

Urticaria are itchy, raised red areas on the skin. Urticaria are caused by a reaction to certain foods, drugs, infections, or emotional stress. Also called hives.

New, previously unknown form of familial cold urticaria discovered

Skin rash combined with head and joint pain: these are the symptoms which patients with familial (hereditary) cold urticaria develop when exposed to temperatures below 15 °C.

27 Apr 2020

Researchers succeed in creating complex pattern of hives

Hives afflict 1 in 5 people, but the exact mechanisms behind the itchy red rashes are not well known. The research team studied the patterns of hives in patients and reproduced the hive patterns using a mathematical model called a reaction-diffusion model, a common prototype for understanding how patterns develop. The researchers' model is a single equation type which had never before been used to generate complex patterns.

28 Jan 2020

Meta-analysis reveals effective treatment options for urticarial vasculitis

What treatments are available for patients with the rare inflammatory disease known as urticarial vasculitis? How effective are these treatments? Researchers from Charité - Universitätsmedizin Berlin embarked on a systematic review and meta-analysis to address these questions.

30 Oct 2018

Study reveals safety, efficacy of brexpiprazole for schizophrenia patients with severe psychotic symptoms

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announced study results on the safety and efficacy of brexpiprazole in the treatment of patients with schizophrenia experiencing severe psychotic symptoms during an acute episode. The data will be presented at the upcoming Psych Congress, held in Orlando from October 25-28, 2018.

26 Oct 2018

Leadiant Biosciences announces FDA approval of Revcovi for treating pediatric, adult ADA-SCID patients

Leadiant Biosciences, Inc. today announced that the Food and Drug Administration has granted approval to Revcovi (elapegademase-lvlr) injection in the U.S. Revcovi is a new enzyme replacement therapy for the treatment of adenosine deaminase severe combined immune deficiency in pediatric and adult patients.

7 Oct 2018

FDA approves Teva’s AJOVY injection for preventive treatment of migraine in adults

Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration has approved AJOVY injection for the preventive treatment of migraine in adults.

17 Sep 2018

New approach to cultivate hypoallergenic tomato and strawberry varieties

The incidence of food allergies has increased in recent decades: It affects three to four percent of the adult population and five percent of children.

16 Jul 2018

New results reinforce COPAXONE 40 mg/mL as safe and effective for RMS patients

Teva Pharmaceutical Industries Ltd., today announced up to 7-year efficacy, safety and tolerability results from the Glatiramer Acetate Low-Frequency Administration (GALA) open-label extension study of COPAXONE (glatiramer acetate injection) 40 mg/mL administered subcutaneously three-times-a-week for the treatment of relapsing forms of multiple sclerosis (RMS).

28 Apr 2018

Acid-suppressing medicines and antibiotics in infancy linked to later allergic disease risk

The use of acid-suppressing medications or antibiotics in the first 6 months of infancy was associated with an increased risk for the subsequent development of allergic diseases in childhood.

2 Apr 2018

AstraZeneca’s new precision biologic gets FDA approval to treat severe eosinophilic asthma

AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration has approved FASENRA (benralizumab) for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.

14 Nov 2017

ACADIA Pharmaceuticals announces results from Phase II study of antipsychotic in Alzheimer's disease psychosis

ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the presentation of data from the Phase II -019 Study of pimavanserin in Alzheimer's disease psychosis at the 10th Clinical Trials on Alzheimer's Disease meeting in Boston.

3 Nov 2017

First-ever treatment for Merkel cell carcinoma receives approval in Japan

Merck KGaA, Darmstadt, Germany, and Pfizer Inc. today announced that the Japanese Ministry of Health, Labor, and Welfare (MHLW) has approved BAVENCIO (avelumab, genetically recombinant Injection 200mg/mL for intravenous use) as the first and only treatment indicated for curatively unresectable Merkel cell carcinoma (MCC), a rare and aggressive cancer, in Japan.

27 Sep 2017

FDA grants accelerated approval to new treatment for children with Chagas disease

The U.S. Food and Drug Administration today granted accelerated approval to benznidazole for use in children ages 2 to 12 years old with Chagas disease. It is the first treatment approved in the United States for the treatment of Chagas disease.

29 Aug 2017

Many chronic urticaria patients are not receiving treatment, Novartis study shows

Novartis announced today new baseline results from a real world study of 3,733 chronic urticaria (CU) patients showing many are not receiving adequate care, with almost half (42%) not receiving any treatment at all for the debilitating disease despite 83% suffering a negative impact on their quality of life.

20 Jun 2017

Steroids offer no additional relief to emergency patients suffering from hives

Despite standard use for the itching associated with urticaria (commonly known as hives), prednisone (a steroid) offered no additional relief to emergency patients suffering from hives than a placebo did, according to a randomized, placebo-controlled, double-blind, parallel-group study published online yesterday in Annals of Emergency Medicine.

4 May 2017

Patients with inducible urticaria can benefit from treatment with asthma drug

Patients who develop itchy wheals in response to cold or friction benefit from treatment with omalizumab, a drug normally used to treat asthma.

7 Apr 2017

‘The Agony of Hives’: WAO to offer complementary live webinar on chronic urticaria

World Allergy Organization will offer a complementary live webinar, “The Agony of Hives”, on April 4, beginning at 13:30:00 Greenwich Mean Time, for World Allergy Week 2017, which will begin on April 2.

3 Apr 2017

Amgen, UCB present romosozumab Phase 2 results at ENDO 2017

Amgen and UCB today announced results from the fourth year of a Phase 2 study showing the efficacy and safety of a second course of treatment with EVENITY™* (romosozumab), an investigational agent for postmenopausal women with osteoporosis.

3 Apr 2017

Contact dermatitis or contact eczema?

There is allergic contact dermatitis, which is mediated through an immune mechanism, this means that the person is specifically allergic to what they have come in to contact with their skin. Their body has had to go through a process whereby they have...

21 Dec 2016

Penicillin allergy testing: an interview with Dr. Eric Macy

Penicillin was one of the first antibiotics developed and has saved millions of lives. First used in the early 1940s, penicillin is still one of the most widely used and least toxic family of antibiotics.

17 Aug 2016